Paper Details

  1. Home
  2. Paper Details

Oral Atenolol for Infantile Hemangioma: Case Series of 46 Infants.

Author: BallonaR, Calderón-CastratX, CastroR, VelásquezF

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case series presents 46 infants successfully treated with oral atenolol, a selective beta-1 blocker, for problematic infantile hemangioma. Atenolol offers an alternative to propranolol, which can cause undesirable side effects in some patients.
Paper Details　
Original Abstract of the Article :
Propranolol, a non-selective beta-blocker, remains the first line of treatment for problematic infantile hemangioma. However, although rarely, a subset of patients experience undesirable side effects, raising interest in other selective beta-blockers. We present a large case series of 46 infants tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ad.2019.03.015

データ提供：米国国立医学図書館（NLM）

Oral Atenolol for Infantile Hemangioma

This study explores the use of [atenolol], a selective beta-1 blocker, as a treatment option for [infantile hemangioma], a common condition in newborns characterized by the presence of benign tumors. The authors present a compelling case series of 46 infants who were successfully treated with oral atenolol, a departure from the traditional use of [propranolol], a non-selective beta-blocker. Imagine the vast desert of medical knowledge, and this study highlights a new path, a new oasis, in the treatment of infantile hemangiomas.

A New Oasis in Hemangioma Treatment

This research suggests that [atenolol] might be a viable alternative to [propranolol] for treating [infantile hemangioma] in some infants. The study's success in treating 46 infants with atenolol is encouraging, and the authors highlight the potential benefits of this approach. However, it is crucial to remember that every camel is unique and requires a tailored approach to treatment.

Navigating Hemangioma Treatment

Navigating the complexities of [hemangioma treatment] is like traversing a vast desert. This study sheds light on a new path, suggesting that [atenolol] might be a viable alternative in some cases. However, it is vital to consult with a healthcare professional to determine the most appropriate course of treatment for your individual situation.

Dr. Camel's Conclusion

The sands of medical knowledge shift and reveal new paths. This study offers a glimpse into a potential alternative in the treatment of infantile hemangiomas. However, seeking professional guidance is always the wisest course of action in such a complex landscape.
Date :
  1. Date Completed 2021-01-20
  2. Date Revised 2021-05-18
Further Info :

Pubmed ID

31759456

DOI: Digital Object Identifier

10.1016/j.ad.2019.03.015

Related Literature

Article Analysis
・Side Effects of atenolol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.